Wu Huailiang, Qiu Zhen, Wang Liyan, Li Wei
Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Biomedicines. 2024 Aug 23;12(9):1942. doi: 10.3390/biomedicines12091942.
Chronic kidney disease (CKD) is a major global health concern. Renal fibrosis, a prevalent outcome regardless of the initial cause, ultimately leads to end-stage renal disease. Glomerulosclerosis and renal interstitial fibrosis are the primary pathological features. Preventing and slowing renal fibrosis are considered effective strategies for delaying CKD progression. However, effective treatments are lacking. Sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide (NAD)-dependent deacetylase belonging to class III histone deacetylases, is implicated in the physiological regulation and protection of the kidney and is susceptible to a diverse array of pathological influences, as demonstrated in previous studies. Interestingly, controversial conclusions have emerged as research has progressed. This review provides a comprehensive summary of the current understanding and advancements in the field; specifically, the biological roles and mechanisms of SIRT1 in regulating renal fibrosis progression. These include aspects such as lipid metabolism, epithelial-mesenchymal transition, oxidative stress, aging, inflammation, and autophagy. This manuscript explores the potential of SIRT1 as a therapeutic target for renal fibrosis and offers new perspectives on treatment approaches and prognostic assessments.
慢性肾脏病（CKD）是一个重大的全球健康问题。肾纤维化是一种无论初始病因如何都普遍存在的结果，最终会导致终末期肾病。肾小球硬化和肾间质纤维化是主要的病理特征。预防和减缓肾纤维化被认为是延缓CKD进展的有效策略。然而，目前缺乏有效的治疗方法。沉默调节蛋白1（SIRT1）是一种依赖烟酰胺腺嘌呤二核苷酸（NAD）的去乙酰化酶，属于Ⅲ类组蛋白去乙酰化酶，参与肾脏的生理调节和保护，并且易受多种病理影响，如先前研究所表明的。有趣的是，随着研究的进展，出现了有争议的结论。本综述全面总结了该领域目前的认识和进展；具体而言，是SIRT1在调节肾纤维化进展中的生物学作用和机制。这些方面包括脂质代谢、上皮-间质转化、氧化应激、衰老、炎症和自噬等。本文探讨了SIRT1作为肾纤维化治疗靶点的潜力，并为治疗方法和预后评估提供了新的视角。
